Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT02110147
- Locations
- ๐บ๐ธ
Children's Hospital of Michigan - Specialty Center Detroit, Detroit, Michigan, United States
๐บ๐ธChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
- Conditions
- Toxicity Due to Chemotherapy
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Wellstat Therapeutics
- Registration Number
- NCT01432301
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110864
- Locations
- ๐บ๐ธ
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
๐บ๐ธCenter for Diabetes and Endocrine Care, Hollywood, Florida, United States
๐บ๐ธGenesis Research International, Longwood, Florida, United States
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110851
- Locations
- ๐บ๐ธ
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
๐บ๐ธUniversity Clinical Research-DeLand, DeLand, Florida, United States
๐บ๐ธCenter for Diabetes and Endocrine Care, Hollywood, Florida, United States
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
- Conditions
- Drug/Agent Toxicity by Tissue/OrganPancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 250
- Registration Number
- NCT00024427
- Locations
- ๐บ๐ธ
Brookwood Medical Center, Birmingham, Alabama, United States
๐บ๐ธComprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธProvidence Saint Joseph Medical Center - Burbank, Burbank, California, United States
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2002-09-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT00044785
- Locations
- ๐บ๐ธ
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States